In the interview with Dmytro Shymkiv, it was mentioned that within 2018 and 2020, Darnytsia, the Ukrainian pharmaceutical company, accomplished 8 studies of generics — bioequivalent drugs for treating diseases of the heart and central nervous system. The majority of work was conducted in Ukraine, and the final stages of testing were completed in European laboratories. The EU research centers set an essential task that is to prove the therapeutic equivalence and safety of medicines developed by Darnytsia closed joint-stock company.
In his comments on test completion, Dmytro Shymkiv — the Chairman of the Board of Directors of the Darnytsia Group pharmaceutical concern — said that the company priorities its responsibility for patients. Due to this, when developing and testing medicines, it was decided to cooperate with European laboratories where bioanalytical research was conducted. Experts from the EU confirmed that Ukrainian generics are entirely consistent with the original drugs in terms of their effectiveness, safety, and patient tolerance.
Dmytro Shymkiv emphasized that when looking for a partner laboratory, the Darnytsia pharmaceutical company was guided by the main criterion — the ability to provide qualified research at a high level following international requirements. To achieve this goal, the bioanalytical center must be supplied with high-tech equipment, an experienced workforce, and possess an impeccable reputation. Czech QUINTA-ANALYTICA s.r.o is one of such highly qualified laboratories. It is considered an innovative, fast-growing, and trusted global leader in pharmaceutical analysis, drug research, development, and clinical trials. Darnytsia Group has been collaborating with this international laboratory for several years. Accordingly, the Darnytsia management is absolutely confident in the reliability of the research results.
Due to Dmytro Shymkiv, such a productive engagement of Ukrainian and European specialists allows us to obtain the maximum quality of domestic medicines and on-time medicines delivery to the market. Owing to the cooperation between Darnytsia and European bioanalytical centers, Ukrainians have the opportunity to purchase effective and safe analogs of expensive drugs at an affordable price.